Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 3
2011 1
2012 2
2016 1
2017 2
2018 3
2019 2
2020 4
2021 5
2022 9
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for van der leest c[au]
Your search for van der Reest C[au] retrieved no results
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
Ter Heine R, van den Heuvel MM, Piet B, Deenen MJ, van der Wekken AJ, Hendriks LEL, Croes S, van Geel RMJM, Jansman FGA, Boshuizen RC, Franssen EJF, Smit AAJ, Dumoulin DW, Oude Munnink TH, Smit EF, Derijks HJ, van der Leest CH, Hendrikx JJMA, Moes DJAR, de Rouw N. Ter Heine R, et al. Among authors: van der leest ch. Target Oncol. 2023 May;18(3):441-450. doi: 10.1007/s11523-023-00958-6. Epub 2023 Apr 21. Target Oncol. 2023. PMID: 37081309 Free PMC article.
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering Kappelle LBM, Ter Elst A, Hashemi SMS, Dingemans AC, van der Leest C, de Langen AJ, van den Heuvel MM, van der Wekken AJ. Zwierenga F, et al. Among authors: van der leest c. Lung Cancer. 2022 Aug;170:133-140. doi: 10.1016/j.lungcan.2022.06.012. Epub 2022 Jun 23. Lung Cancer. 2022. PMID: 35777160 Free article. Clinical Trial.
[In-hospital treatment of COVID-19 patients].
de Wee EM, van der Sar-van der Brugge S, Grootenboers M, Bentvelsen RG, Kant KM, van der Leest CH. de Wee EM, et al. Among authors: van der leest ch. Ned Tijdschr Geneeskd. 2020 Jul 1;164:D4965. Ned Tijdschr Geneeskd. 2020. PMID: 32608926 Dutch.
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
Basak EA, de Joode K, Uyl TJJ, van der Wal R, Schreurs MWJ, van den Berg SAA, Oomen-de Hoop E, van der Leest CH, Chaker L, Feelders RA, van der Veldt AAM, Joosse A, Koolen SLW, Aerts JGJV, Mathijssen RHJ, Bins S. Basak EA, et al. Among authors: van der leest ch. Biomed Pharmacother. 2022 Dec;156:113839. doi: 10.1016/j.biopha.2022.113839. Epub 2022 Oct 11. Biomed Pharmacother. 2022. PMID: 36228374 Free article.
The development of the ADO-SQ model to predict 1-year mortality in patients with COPD.
Owusuaa C, van der Leest C, Helfrich G, Heller-Baan R, Loenhout CV, Herbrink JW, Nieboer D, van der Rijt CC, van der Heide A. Owusuaa C, et al. Among authors: van der leest c. Palliat Med. 2022 May;36(5):821-829. doi: 10.1177/02692163221080662. Epub 2022 Mar 24. Palliat Med. 2022. PMID: 35331047 Free PMC article.
Improving the tolerability of osimertinib by identifying its toxic limit.
Agema BC, Veerman GDM, Steendam CMJ, Lanser DAC, Preijers T, van der Leest C, Koch BCP, Dingemans AC, Mathijssen RHJ, Koolen SLW. Agema BC, et al. Among authors: van der leest c. Ther Adv Med Oncol. 2022 Jun 3;14:17588359221103212. doi: 10.1177/17588359221103212. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35677320 Free PMC article.
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
van Veelen A, Veerman GDM, Verschueren MV, Gulikers JL, Steendam CMJ, Brouns AJWM, Dursun S, Paats MS, Tjan-Heijnen VCG, van der Leest C, Dingemans AC, Mathijssen RHJ, van de Garde EMW, Souverein P, Driessen JHM, Hendriks LEL, van Geel RMJM, Croes S. van Veelen A, et al. Among authors: van der leest c. Int J Cancer. 2024 Jan 15;154(2):332-342. doi: 10.1002/ijc.34742. Epub 2023 Oct 15. Int J Cancer. 2024. PMID: 37840304
34 results